ZLDPF (Zealand Pharma AS) EBIT: $1,076 Mil (TTM As of Mar. 2026)


ZLDPF Zealand Pharma AS ZLDPF
62 GF Score
Price $42.89
GF Value $1,948.90
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Zealand Pharma AS EBIT?

Zealand Pharma AS ZLDPF 62 EBIT is $1,076 Mil as of Mar. 2026. GuruFocus rates ZLDPF with a GF Score™ of 62/100 and a GF Value™ of $1,948.90 (Possible Value Trap). The stock has 3 warning signs investors should review.

Zealand Pharma AS's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was $-60 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was $1,076 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Zealand Pharma AS's annualized ROC % for the quarter that ended in Mar. 2026 was -348.45%. Zealand Pharma AS's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -980.18%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Zealand Pharma AS's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 126.94%.

Zealand Pharma AS  (OTCPK:ZLDPF) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Zealand Pharma AS's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-333.472 * ( 1 - 0% )/( (89.474 + 101.928)/ 2 )
=-333.472/95.701
=-348.45 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2500.439 - 58.471 - ( 2368.746 - max(0, 104.253 - 2456.747+2368.746))
=89.474

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2366.634 - 26.913 - ( 2237.793 - max(0, 62.487 - 2322.862+2237.793))
=101.928

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Zealand Pharma AS's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-240.668/( ( (23.741 + max(-57.909, 0)) + (25.366 + max(-4.3320000000001, 0)) )/ 2 )
=-240.668/( ( 23.741 + 25.366 )/ 2 )
=-240.668/24.5535
=-980.18 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.053 + 0 + 42.743) - (58.471 + 0 + 42.234)
=-57.909

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.773 + 0 + 52.897) - (26.913 + 0 + 31.089)
=-4.3320000000001

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Zealand Pharma AS's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=1075.797/847.502
=126.94 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zealand Pharma AS EBIT Related Terms

Zealand Pharma AS EBIT Historical Data

* Premium members only.

The historical data trend for Zealand Pharma AS's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zealand Pharma AS EBIT Chart

Zealand Pharma AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -114.69 -130.37 -99.94 -147.34 1,102.18

Zealand Pharma AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -47.54 1,255.16 -56.57 -62.62 -60.17

ZLDPF vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, Zealand Pharma AS's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zealand Pharma AS EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zealand Pharma AS's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Zealand Pharma AS's EV-to-EBIT falls into.


ZLDPF
62GF Score
Zealand Pharma AS ZLDPF
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zealand Pharma AS EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,076 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $1,076 Mil mean?
Zealand Pharma AS (ZLDPF) has a EBIT of $1,076 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Zealand Pharma AS.
Is Zealand Pharma AS's EBIT too high?
Zealand Pharma AS's current EBIT is $1,076 Mil. Overall, Zealand Pharma AS has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Zealand Pharma AS's EBIT compare to VRTX and REGN?
Zealand Pharma AS's EBIT of $1,076 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Zealand Pharma AS. Zealand Pharma AS's current EBIT is $1,076 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zealand Pharma AS stock overvalued right now?
Based on GuruFocus' analysis, Zealand Pharma AS (ZLDPF) is currently considered Possible Value Trap. The stock's GF Value™ is $1,948.90, compared to a current price of $42.89 — trading 97.8% below its estimated fair value. The current EBIT is $1,076 Mil. Zealand Pharma AS's overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Zealand Pharma AS (ZLDPF), the current EBIT is $1,076 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zealand Pharma AS (ZLDPF) Overvalued in 2026?

Based on GuruFocus' analysis, Zealand Pharma AS stock appears to be undervalued. The current stock price of $42.89 is trading 97.8% below its estimated GF Value™ of $1,948.90. GuruFocus considers Zealand Pharma AS to be Possible Value Trap.

Key valuation signals for ZLDPF:

  • EBIT: $1,076 Mil
  • GF Value™: $1,948.90 vs. price of $42.89 (97.8% below fair value)
  • GF Score™: 62/100 with 3 warning signs

No single metric tells the full story. See the ZLDPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zealand Pharma AS Business Description

Address Sydmarken 11, Soborg, DNK, DK-2860
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.
62GF Score

Get the complete analysis for ZLDPF

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$42.89
Price
$1,948.90
GF Value